Cargando…

Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease

Metabolic-associated fatty liver disease (MAFLD) and diabetic kidney disease (DKD) share various pathophysiological factors, and epidemiological evidence suggests that these two diseases are associated. Albuminuria and the estimated glomerular filtration rate, which are conventional biomarkers of DK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bae, Jaehyun, Lee, Byung-Wan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377561/ https://www.ncbi.nlm.nih.gov/pubmed/37509567 http://dx.doi.org/10.3390/biomedicines11071928

Ejemplares similares

Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
por: Bae, Jaehyun, et al.
Publicado: (2023)

Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes
por: Lee, Sejeong, et al.
Publicado: (2023)

Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
por: Bae, Jaehyun, et al.
Publicado: (2021)

The effects of the voglibose on non-alcoholic fatty liver disease in mice model
por: Bae, Jaehyun, et al.
Publicado: (2022)

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
por: Alharthi, Jawaher, et al.
Publicado: (2022)

Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease
por: Jiang, Hua, et al.
Publicado: (2023)

A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis
por: Bessho, Rieko, et al.
Publicado: (2022)

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
por: Kim, Kyung-Soo, et al.
Publicado: (2020)

Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
por: Hashimoto, Yoshitaka, et al.
Publicado: (2021)

Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease
por: Su, Weitao, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
por: Kim, Kyung-Soo, et al.
Publicado: (2019)

A Study of Biomarkers Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Type 2 Diabetes
por: Efrem, Ion Cristian, et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease reflects a significantly higher risk of hypertension than non-alcoholic fatty liver disease
por: Uehara, Tatsuki, et al.
Publicado: (2023)

Metabolic-associated Fatty Liver Disease
por: Zheng, Ming-Hua
Publicado: (2021)

Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease
por: Jeong, Seogsong, et al.
Publicado: (2022)

Combined Effects of Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease on the Risk of Cardiovascular Disease in Patients with Diabetes
por: Chung, Goh-Eun, et al.
Publicado: (2022)

Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease
por: Chung, Goh Eun, et al.
Publicado: (2023)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
por: Lee, Yong-ho, et al.
Publicado: (2019)

Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome
por: Kositamongkol, Chayanis, et al.
Publicado: (2021)

Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
por: Yu, Su Jong, et al.
Publicado: (2015)

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
por: Kang, Seong Hee, et al.
Publicado: (2021)

Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus
por: Miyake, Teruki, et al.
Publicado: (2022)

Metabolic-associated fatty liver disease and lipoprotein metabolism
por: Heeren, Joerg, et al.
Publicado: (2021)

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Seo, Da Hea, et al.
Publicado: (2022)

Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
por: Drożdż, Karolina, et al.
Publicado: (2021)

Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease
por: Choe, A Reum, et al.
Publicado: (2020)

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
por: Lee, Byung-Wan, et al.
Publicado: (2020)

Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Kim, Gyuri, et al.
Publicado: (2015)

Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
por: Li, Na, et al.
Publicado: (2021)

Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?
por: Devi, Jalpa, et al.
Publicado: (2022)

Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity
por: Pirola, Carlos J, et al.
Publicado: (2018)

Macrophages in metabolic associated fatty liver disease
por: Alharthi, Jawaher, et al.
Publicado: (2020)

Alcohol and Metabolic-associated Fatty Liver Disease
por: Sun, Fu-Rong, et al.
Publicado: (2021)

The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study
por: Lee, Seung Eun, et al.
Publicado: (2023)

The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease
por: Seo, Ji-Yeon, et al.
Publicado: (2021)

Significant Association between Subclinical Left Cardiac Dysfunction and Liver Stiffness in Metabolic Syndrome Patients with Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
por: Apostu, Alexandru, et al.
Publicado: (2023)

Problems and Challenges Associated with Renaming Non-alcoholic Fatty Liver Disease to Metabolic Associated Fatty Liver Disease
por: Zeng, Minghui, et al.
Publicado: (2023)

Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents
por: Ciardullo, Stefano, et al.
Publicado: (2022)

New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease
por: Lin, Yu-Cheng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o45akg9lrgge2nnpjqi06nagnl